https://mindmedicinelaw.com/briefing/medicare-fy-2027-update-implications-for-psychedelic-therapies-20260731-27600The Psychedelic Journalen2026-07-31T22:05:55.979315+00:00Medicare FY 2027 Update: Implications for Psychedelic Therapiesmedicare update, inpatient psychiatric facilities, psychedelic therapies, payment rates, quality measures, psychiatric care, healthcare policy, psychedelic integration, financial incentives, treatment modalitieshttps://mindmedicinelaw.com/briefing/ketamine-guidelines-for-chronic-pain-a-scoping-review-20260730-27744The Psychedelic Journalen2026-07-31T22:06:13.897782+00:00Ketamine Guidelines for Chronic Pain: A Scoping Reviewketamine guidelines, chronic pain management, non-cancer pain, clinical protocols, NMDA receptor antagonist, patient safety, standardized treatment, pharmacological action, policy implications, research directionshttps://mindmedicinelaw.com/briefing/esketamine-nasal-spray-for-ect-refractory-bipolar-depression-20260730-27847The Psychedelic Journalen2026-07-31T22:06:04.215183+00:00Esketamine Nasal Spray for ECT-Refractory Bipolar Depressionesketamine nasal spray, ECT-refractory depression, bipolar depression treatment, treatment-resistant mood disorders, NMDA receptor antagonist, psychiatric researchhttps://mindmedicinelaw.com/briefing/esketamine-s-potential-in-cancer-related-depression-a-review-20260730-27805The Psychedelic Journalen2026-07-31T22:05:39.885026+00:00Esketamine's Potential in Cancer-Related Depression: A Reviewesketamine, cancer-related depression, rapid-acting antidepressant, NMDA receptor, BDNF, oncology care, synaptic plasticity, clinical trials, safety and efficacyhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-veterans-with-ptsd-clinical-trial-insights-20260730-27804The Psychedelic Journalen2026-07-31T22:05:31.974635+00:00Psilocybin Therapy for Veterans with PTSD: Clinical Trial Insightspsilocybin-assisted therapy, veterans, PTSD, clinical trial, treatment-resistant, mental health, psychedelic research, safety and efficacy, therapy integration, U.S. militaryhttps://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-may-impact-psychedelic-research-20260730-27293The Psychedelic Journalen2026-07-30T15:05:48.574182+00:00EPA's Proposed SNURs May Impact Psychedelic ResearchEPA, SNURs, psychedelic research, chemical substances, TSCA, regulatory compliance, manufacture, import, notification period, regulatory frameworkhttps://mindmedicinelaw.com/briefing/ketamine-s-rapid-antidepressant-effects-clinical-insights-20260729-27676The Psychedelic Journalen2026-07-31T15:09:10.101574+00:00Ketamine's Rapid Antidepressant Effects: Clinical Insightsketamine, treatment-resistant depression, rapid antidepressant effects, NMDA receptor antagonist, long-term safety, optimal dosing, psychiatric treatment, clinical trials, neuropharmacology, glutamatergic signalinghttps://mindmedicinelaw.com/briefing/esketamine-enhances-postoperative-sleep-in-laparoscopic-surgery-20260729-27678The Psychedelic Journalen2026-07-31T15:08:57.825676+00:00Esketamine Enhances Postoperative Sleep in Laparoscopic Surgeryesketamine, postoperative sleep, laparoscopic surgery, opioid reduction, anesthesia, clinical trial, pain management, Huzhou Maternity & Child Health Care Hospital, Pittsburgh Sleep Quality Index, NMDA receptor antagonismhttps://mindmedicinelaw.com/briefing/ketamine-trial-in-suicidal-adolescents-feasibility-in-ed-20260729-27677The Psychedelic Journalen2026-07-31T15:08:19.473347+00:00Ketamine Trial in Suicidal Adolescents: Feasibility in EDketamine, suicidal adolescents, emergency department, clinical trials, psychiatric care, treatment-resistant depression, intravenous administration, adverse effects, rapid-acting antidepressant, mental health researchhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-post-amputation-pain-management-20260729-27414The Psychedelic Journalen2026-07-30T15:05:58.218615+00:00Ketamine's Role in Post-Amputation Pain Managementketamine infusions, postoperative pain management, opioid reduction, limb amputation, public health policy, NMDA receptor, opioid crisis, pain management protocols, clinical trials, ketamine side effectshttps://mindmedicinelaw.com/briefing/psilocybin-microdosing-alters-epigenetics-in-rat-brain-20260728-27670The Psychedelic Journalen2026-07-31T22:05:47.760674+00:00Psilocybin Microdosing Alters Epigenetics in Rat Brainpsilocybin microdosing, epigenetic changes, rat brain, neuroplasticity, mood disorders, anxiety disorders, serotonin receptor, histone acetylation, clinical research, psychedelic therapyhttps://mindmedicinelaw.com/briefing/eeg-biomarkers-in-psilocybin-treatment-for-depression-20260728-27639The Psychedelic Journalen2026-07-31T15:09:21.954924+00:00EEG Biomarkers in Psilocybin Treatment for Depressionpsilocybin, EEG, MEG, depression treatment, biomarkers, clinical trials, neural oscillations, mental health, predictive biomarkers, neurophysiologyhttps://mindmedicinelaw.com/briefing/key-factors-in-psilocybin-effects-in-mouse-models-identified-20260728-27669The Psychedelic Journalen2026-07-31T15:08:32.040100+00:00Key Factors in Psilocybin Effects in Mouse Models Identifiedpsilocybin, mouse models, behavioral effects, preclinical research, biological factors, experimental variables, psychiatric treatment, 5-HT1B signaling, translational relevance, therapeutic modelshttps://mindmedicinelaw.com/briefing/ssri-dynamics-in-ocd-a-new-model-for-treatment-response-20260727-27145The Psychedelic Journalen2026-07-30T15:06:06.834762+00:00SSRI Dynamics in OCD: A New Model for Treatment ResponseSSRI treatment, obsessive-compulsive disorder, bistable dynamics, clinical trials, individual response, treatment remission, neuroscience, pharmacokinetics, OCD model, treatment strategieshttps://mindmedicinelaw.com/briefing/entropic-brain-hypothesis-new-insights-from-diverse-states-20260726-27692The Psychedelic Journalen2026-07-31T15:08:47.170279+00:00Entropic Brain Hypothesis: New Insights from Diverse Statesentropic brain hypothesis, psychedelics, consciousness, brain activity entropy, LSD, DMT, mental health, fMRI, neuroscience, therapeutic applicationshttps://mindmedicinelaw.com/briefing/chlorogenic-acid-s-effects-on-ketamine-induced-schizophrenia-in-rats-20260724-27480The Psychedelic Journalen2026-07-30T22:04:55.748468+00:00Chlorogenic Acid's Effects on Ketamine-Induced Schizophrenia in Ratschlorogenic acid, ketamine, schizophrenia, neuropsychiatric disorders, rats, BDNF expression, sex-dependent effects, dietary interventions, prefrontal cortex, behavioral changeshttps://mindmedicinelaw.com/briefing/social-hierarchy-influences-stress-and-ketamine-effects-in-mice-20260721-27534The Psychedelic Journalen2026-07-30T22:05:07.171327+00:00Social Hierarchy Influences Stress and Ketamine Effects in Micesocial hierarchy, stress response, ketamine treatment, psychiatric disorders, mice study, personalized medicine, transcriptional response, dominant individuals, chronic stress, behavioral alterations